(Q38169643)

24319186

30 August 2017

title

Bringing natural killer cells to the clinic: ex vivo manipulation (English)

1 reference

30 August 2017

Richard W Childs

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6610030&resulttype=core&format=json

15 May 2020

Maria Berg

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6610030&resulttype=core&format=json

15 May 2020

language of work or name

1 reference

1 January 2013

1 reference

24319186

Hematology / the Education Program of the American Society of Hematology

30 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6610030&resulttype=core&format=json

15 May 2020

volume

2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6610030&resulttype=core&format=json

15 May 2020

page(s)

234-246

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6610030&resulttype=core&format=json

A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells

15 May 2020

cites work

1 reference

12 December 2020

Immunomodulatory therapy for melanoma: ipilimumab and beyond

1 reference

12 December 2020

Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process

1 reference

12 December 2020

IL-18-induced CD83+CCR7+ NK helper cells

1 reference

12 December 2020

Replicative potential of human natural killer cells

1 reference

12 December 2020

IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect

1 reference

12 December 2020

Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas

1 reference

12 December 2020

Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells

1 reference

12 December 2020

Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation

1 reference

12 December 2020

Permanent silencing of NKG2A expression for cell-based therapeutics

1 reference

12 December 2020

Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens

1 reference

12 December 2020

Hemolytic anemia due to passenger lymphocyte syndrome in solid malignancy patients treated with allogeneic natural killer cell products.

1 reference

12 December 2020

Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling

1 reference

12 December 2020

Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells

1 reference

12 December 2020

A Wilms tumor cell line, HFWT, can greatly stimulate proliferation of CD56+ human natural killer cells and their novel precursors in blood mononuclear cells

1 reference

12 December 2020

Inhibition of intracellular antiviral defense mechanisms augments lentiviral transduction of human natural killer cells: implications for gene therapy.

1 reference

12 December 2020

Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients

1 reference

12 December 2020

Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation

1 reference

12 December 2020

Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity

1 reference

12 December 2020

Expansion, purification, and functional assessment of human peripheral blood NK cells

1 reference

12 December 2020

Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7.

1 reference

12 December 2020

Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity

1 reference

12 December 2020

Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components

1 reference

12 December 2020

Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells

1 reference

12 December 2020

Clinical production and therapeutic applications of alloreactive natural killer cells.

1 reference

12 December 2020

Immunotherapy with interleukin-2 (IL2) and lymphokine-activated natural killer cells: improvement of clinical responses in metastatic renal cell carcinoma patients previously treated with IL2.

1 reference

12 December 2020

Preferential proliferation of natural killer cells among peripheral blood mononuclear cells cocultured with B lymphoblastoid cell lines

1 reference

12 December 2020

Retroviral gene transfer into primary human natural killer cells

1 reference

12 December 2020

Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience

1 reference

12 December 2020

Natural killer cell differentiation from hematopoietic stem cells: a comparative analysis of heparin- and stromal cell-supported methods

1 reference

12 December 2020

Cutting edge: bortezomib-treated tumors sensitized to NK cell apoptosis paradoxically acquire resistance to antigen-specific T cells

1 reference

12 December 2020

IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation

1 reference

12 December 2020

Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.

1 reference

12 December 2020

Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression

1 reference

12 December 2020

Prospects for the use of NK cells in immunotherapy of human cancer.

1 reference

12 December 2020

Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells

1 reference

12 December 2020

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

1 reference

12 December 2020

Ex vivo expansion of natural killer cells for clinical applications

1 reference

12 December 2020

At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy

1 reference

12 December 2020

NK cells--from bench to clinic

1 reference

12 December 2020

Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity

1 reference

12 December 2020

A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies

1 reference

12 December 2020

Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells

1 reference

12 December 2020

Ex-vivo expansion of NK cells: what is the priority--high yield or high purity?

1 reference

12 December 2020

Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy

1 reference

12 December 2020

Highly activated and expanded natural killer cells for multiple myeloma immunotherapy

1 reference

12 December 2020

NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia

1 reference

12 December 2020

Generation of a cloned NK cell line derived from the "null cell" fraction of human peripheral blood.

1 reference

12 December 2020

Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers.

1 reference

12 December 2020

Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells

1 reference

12 December 2020

2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells

1 reference

12 December 2020

Differentiation of natural killer (NK) cells from human primitive marrow progenitors in a stroma-based long-term culture system: identification of a CD34+7+ NK progenitor.

1 reference

12 December 2020

Expansion of highly cytotoxic human natural killer cells for cancer cell therapy

1 reference

12 December 2020

The lymphocyte homing receptors: gatekeepers of the multistep paradigm

1 reference

12 December 2020

Natural killer cell engineering for cellular therapy of cancer

1 reference

12 December 2020

Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone

1 reference

12 December 2020

Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor

1 reference

12 December 2020

Large-scale generation of natural killer lymphocytes for clinical application

1 reference

12 December 2020

Genetic modification of natural killer cells for adoptive cellular immunotherapy.

1 reference

12 December 2020

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

1 reference

12 December 2020

Natural killer cell immunotherapy for cancer: a new hope

1 reference

12 December 2020

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

1 reference

12 December 2020

Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients

1 reference

12 December 2020

Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients

1 reference

12 December 2020

Ex vivo activation and expansion of natural killer cells from patients with advanced cancer with feeder cells from healthy volunteers

1 reference

12 December 2020

The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production

1 reference

12 December 2020

Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications

1 reference

12 December 2020

Increased proliferation, lytic activity, and purity of human natural killer cells cocultured with mitogen-activated feeder cells

1 reference

12 December 2020

Natural killer cell alloreactivity 10 years later

1 reference

12 December 2020

Allogeneic natural killer cells for refractory lymphoma

1 reference

12 December 2020

Generation of natural killer cells from hematopoietic stem cells in vitro for immunotherapy

1 reference

12 December 2020

10.1182/ASHEDUCATION-2013.1.234

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6610030&resulttype=core&format=json

15 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6610030&resulttype=core&format=json

15 May 2020

24319186

1 reference